PT. RICHMOND, Calif., Nov. 14 /PRNewswire/ -- Transcept
 Pharmaceuticals, Inc. today announced that Thomas P. Soloway, Senior Vice
 President and Chief Financial Officer, will present at the 19th Annual
 Piper Jaffray Health Care Conference at the Pierre Hotel in New York City
 on Tuesday, November 27, 2007 at 10:30 AM Eastern Time.
     About Transcept Pharmaceuticals
     Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company
 deriving significant new patient benefits from proven CNS drugs. Transcept
 development projects leverage new understanding of CNS conditions to
 provide additional uses and enhanced clinical benefits for existing active
 agents. The lead Transcept product, Intermezzo(R) (zolpidem tartrate
 lozenge), is a low dose sublingual formulation of zolpidem that is
 currently in late phase 3 clinical trials for the treatment of insomnia in
 patients who awaken in the middle of the night and have difficulty
 returning to sleep. Another product being developed by Transcept is
 TO-2060, a novel, fixed-dose combination of olanzapine and ondansetron for
 the treatment of dopamine associated psychiatric disorders. TO-2060 is
 currently the subject of an initial proof of concept trial in the treatment
 of alcohol use disorder. For more information, please visit the company's
 website at: http://www.transcept.com.
      Contacts:
 
      Transcept Pharmaceuticals, Inc.        The Ruth Group
      Michael Gill,                          Investors / Media
      Director of Communications             Stephanie Carrington / Jason Rando
      (510) 215-3575                         (646) 536-7017 / 7025
      mgill@transcept.com                    scarrington@theruthgroup.com
                                             jrando@theruthgroup.com
 
 

SOURCE Transcept Pharmaceuticals, Inc.

Back to top